Nyxoah SA (NASDAQ:NYXH) Short Interest Update

by · The Markets Daily

Nyxoah SA (NASDAQ:NYXH – Get Free Report) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totaling 826,117 shares, a growth of 185.5% from the May 31st total of 289,376 shares. Based on an average daily volume of 965,701 shares, the short-interest ratio is currently 0.9 days. Approximately 2.6% of the shares of the stock are short sold.

Analysts Set New Price Targets

Several equities analysts have issued reports on NYXH shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price objective on shares of Nyxoah in a research report on Monday, March 23rd. Piper Sandler restated an “overweight” rating and issued a $7.00 target price (down from $9.00) on shares of Nyxoah in a research note on Wednesday, May 13th. Weiss Ratings cut Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. Finally, Stifel Nicolaus cut their price target on Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a report on Wednesday, June 17th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.00.

Get Our Latest Analysis on Nyxoah

Nyxoah Trading Up 2.5%

NASDAQ:NYXH traded up $0.04 during trading hours on Friday, hitting $1.67. 112,734 shares of the stock were exchanged, compared to its average volume of 705,644. The company’s 50 day moving average is $2.54 and its two-hundred day moving average is $3.63. Nyxoah has a twelve month low of $1.26 and a twelve month high of $8.59. The company has a quick ratio of 0.88, a current ratio of 0.99 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $64.73 million, a P/E ratio of -0.67 and a beta of 1.55.

Nyxoah (NASDAQ:NYXH – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.11. The company had revenue of $7.38 million during the quarter, compared to analysts’ expectations of $7.05 million. Nyxoah had a negative return on equity of 163.73% and a negative net margin of 543.21%. On average, sell-side analysts anticipate that Nyxoah will post -1.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nyxoah

Several hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. increased its position in Nyxoah by 35.6% in the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after purchasing an additional 3,353 shares during the period. Bank of America Corp DE lifted its position in Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after purchasing an additional 3,303 shares during the period. Citadel Advisors LLC acquired a new position in Nyxoah during the 3rd quarter valued at about $98,000. Deutsche Bank AG boosted its stake in shares of Nyxoah by 40.0% in the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Shay Capital LLC bought a new position in shares of Nyxoah in the 2nd quarter valued at about $374,000.

About Nyxoah

(Get Free Report)

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.

Featured Articles